间充质干细胞治疗新型冠状病毒肺炎的潜在机制和研究进展

doi:10.6040/j.issn.1671-7554.0.2020.224

摘要/Abstract

摘要： 当前新型冠状病毒肆虐,严重危害人类健康、社会经济发展及全球医疗和公共卫生系统。新型冠状病毒传染性强,潜伏期长,疫情控制难度大,引起重症、危重症及死亡病例众多,尚缺乏有效特异性治疗。过度的免疫反应引起的细胞因子风暴是新型冠状病毒感染导致急性呼吸窘迫综合征、脓毒症休克和多器官衰竭甚至死亡的关键因素。间充质干细胞具有强大的抗炎及免疫调节功能,可抑制细胞因子风暴的发生、发展,同时亦有强大的组织损伤修复的能力,双管齐下可发挥减轻肺损伤、降低急性呼吸窘迫综合征等严重并发症发生风险,有望降低患者的死亡率。目前已启动了多项间充质干细胞治疗新型冠状病毒肺炎的相关临床研究项目,初步证实了安全性及有效性,提示具有良好临床应用前景。

关键词: 新型冠状病毒肺炎, 间充质干细胞, 免疫调节, 损伤修复, 细胞因子风暴综合征

Abstract: The current spread of 2019 novel coronavirus pneumonia(2019-nCoV)seriously endangers human health, socio-economic development, as well as the global medical and public health system. The 2019-nCoV is highly contagious and lethal, characterized by long incubation period and difficulty control. More importantly, there is no specific and effective treatment for this disease so far. The cytokine storm caused by excessive immune response is a key factor leading to acute respiratory distress syndrome, septic shock, multiple organ failure, and even death. As mesenchymal stem cells(MSCs)have powerful anti-inflammatory and immunoregulatory potentials, which can inhibit the occurrence and development of cytokine storms and repair tissue damage, MSCs are expected to reduce lung injury, severe complications and mortality. The academic institutes in China have initiated several clinical research projects on MSCs for the treatment of 2019-nCoV, and have preliminarily confirmed its safety, effectiveness and clinical prospect.

Key words: Novel coronavirus pneumonia, Mesenchymal stem cells, Immune regulation, Damage repair, Cytokine storm syndrome

中图分类号:

R563.1

鞠秀丽. 间充质干细胞治疗新型冠状病毒肺炎的潜在机制和研究进展[J]. 山东大学学报 (医学版), 2020, 58(3): 32-37.

JU Xiuli. Potential mechanism and research progress of mesenchymal stem cells in the treatment of 2019 novel coronavirus pneumonia[J]. Journal of Shandong University (Health Sciences), 2020, 58(3): 32-37.

参考文献 34

[1]	国家卫生健康委办公厅.新型冠状病毒感染的肺炎诊疗方案(试行第六版)[EB/OL].(2020-02-18)[2020-02-19].http://www.gov.cn/zhengce/zhengceku/2020-02/19/content_5480948.htm.
[2]	Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019 [J]. N Engl J Med, 2020, 382(8): 727-733.
[3]	Wang C, Horby PW, Hayden FG, et al. A novel coronavirus outbreak of global health concern [J]. Lancet, 2020, 395(10223):470-473.
[4]	Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study [J]. Lancet, 2020, 395(10223):507-513.
[5]	Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding[J]. Lancet,2020,395(10224):565-574.
[6]	Daniel Wrapp, Nianshuang Wang, Kizzmekia S, et al. Cryo-EM Structure of the 2019-nCoV Spike in the Prefusion Conformation[EB/OL].(2020-02-11)[2020-02-19]. doi: 10.1101/2020.02.11.944462.
[7]	张艳丽, 蒋澄宇. 细胞因子风暴:急性呼吸窘迫综合征中的主宰生命之手[J]. 生命科学, 2015, 27(5):554-557. ZHANG Yanli, JIANG Chengyu. Cytokine storm in ARDS[J]. Chinese Bulletin of Life Sciences, 2015, 27(5):554-557.
[8]	Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China [J]. Lancet, 2020, 395(10223):497-506.
[9]	Shinya K, Gao Y, Cilloniz C, et al. Integrated clinical, pathologic, virologic, and transcriptomic analysis of H5N1 influenza virus-induced viral pneumonia in the rhesus macaque[J]. J Virol, 2012, 86(11): 6055-6066.
[10]	Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome [J]. Lancet Respir Med, 2020. doi: 10.1016/S2213-2600(20)30076-X.
[11]	Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease[J]. Nat Rev Immunol, 2008, 8(9):726-736.
[12]	Uccelli A, de Rosbo NK. The immunomodulatory function of mesenchymal stem cells: mode of action and pathways[J]. Ann N Y Acad Sci, 2015, 1351: 114-126. doi: 10.1111/nyas.12815.
[13]	Fu X, Liu G, Halim A, et al. Mesenchymal stem cell migration and tissue repair[J]. Cells, 2019, 8(8):784.
[14]	Qin ZH, Xu JF, Qu JM, et al. Intrapleural delivery of MSCs attenuates acute lung injury by paracrine/endocrine mechanism [J]. J Cell Mol Med, 2012, 16(11):2745-2753.
[15]	Curley GF, Hayes M, Ansari B, et al. Mesenchymal stem cells enhance recovery and repair following ventilatorinduced lung injury in the rat[J]. Thorax, 2012, 67(6):496-501.
[16]	Antunes MA, Abreu SC, Cruz FF, et al. Effects of different mesenchymal stromal cell sources and delivery routes in experimental emphysema[J]. Respir Res, 2014, 15: 118. doi: 10.1186/s12931-014-0118-x.
[17]	Antebi B, Mohammadipoor A, Batchinsky AI, et al. The promise of mesenchymal stem cell therapy for acute respiratory distress syndrome [J]. J Trauma Acute Care Surg, 2018, 84(1): 183-191.
[18]	Wu X, Dao Thi VL, Huang Y, et al. Intrinsic immunity shapes viral resistance of stem cells[J]. Cell, 2018, 172(3):423-438.
[19]	Sobacchi C, Palagano E, Villa A, et al. Soluble factors on stage to direct mesenchymal stem cells fate[J]. Front Bioeng Biotechnol, 2017, 5(32): 1-9.
[20]	Ethokic JM, Tomic SZ, Colic MJ. Cross-talk between mesenchymal stem/stromal cells and dendritic cells [J]. Curr Stem Cell Res Ther, 2016, 11(1): 51-65.
[21]	Wang G, Cao K, Liu K, et al. Kynurenic acid, an IDO metabolite, controls TSG-6-mediated immunosuppression of human mesenchymal stem cells[J]. Cell Death Differ, 2018, 25(7):1209-1223.
[22]	Song Y, Dou H, Li X, et al. Exosomal miR-146a contributes to the enhanced therapeutic efficacy of IL-1β-primed mesenchymal stem cells against sepsis: IL-1β enhances immunomodulatory effect of MSCs[J]. Stem Cells, 2017, 35(5): 1208-1221.
[23]	Li S, Wu H, Han D, et al. A novel mechanism of mesenchymal stromal cell-mediated protection against sepsis: restricting inflammasome activation in macrophages by increasing mitophagy and decreasing mitochondrial ROS[J]. Oxid Med Cell Longev, 2018, 4(13): 3537609-3537623.
[24]	Fayyad-Kazan H, Faour WH, Badran B, et al. The immunomodulatory properties of human bone marrowderived mesenchymal stromal cells are defined according to multiple immunobiological criteria [J]. Inflamm Res, 2016, 65(6): 501-510.
[25]	Zanotti L, Angioni R, Cali B, et al. Mouse mesenchymal stem cells inhibit high endothelial cell activation and lymphocyte homing to lymph nodes by releasing TIMP-1[J]. Leukemia, 2016, 30(5): 1143-1154.
[26]	Li B, Zhang H, Zeng M, et al. Bone marrow mesenchymal stem cells protect alveolar macrophages from lipopolysaccharideinduced apoptosis partially by inhibiting the Wnt/β-catenin pathway[J]. Cell Biology International, 2015, 39(2): 192-200.
[27]	Rojas M, Xu J, Woods CR, et al. Bone marrow-derived mesenchymal stem cells in repair of the injured lung [J]. Am J Respir Cell Mol Biol, 2005, 33(2): 145-152.
[28]	Lee JW, Fang X, Gupta N, et al. Allogeneic human mesenchymal stem cells for treatment of E. Coli endotoxin-induced acute lung injury in the ex vivo perfused human lung [J]. Proc Natl Acad Sci USA, 2009, 106(38): 16357-16362.
[29]	Yang Y, Hu S, Xu X, et al. The vascular endothelial growth factors-expressing character of mesenchymal stem cells plays a positive role in treatment of acute lung injury in vivo[J]. Mediators Inflamm, 2016, 2016:2347938.doi: 10.1155/2016/2347938.
[30]	LI QC, LIANG Y, SU ZB. Prophylactic treatment with MSC-derived exosomes attenuates traumatic acute lung injury in rats[J]. Am J Physiol Lung Cell Mol Physiol, 2019, 316(6):1107-1117.
[31]	Loy H, Kuok DIT, Hui KPY, et al. Therapeutic implications of human umbilical cord mesenchymal stromal cells in attenuating influenza A(H5N1)virusassociated acute lung injury [J]. J Infect Dis, 2019, 219(2):186-196.
[32]	Zhang X, Gao F, Li Q, et al. MSCs with ACE II gene affect apoptosis pathway of acute lung injury induced by bleomycin[J]. Exp Lung Res, 2015, 41(1):32-43.
[33]	Wilson JG, Liu KD, Zhuo H, et al. Mesenchymal stem(stromal)cells for treatment of ARDS: a phase 1 clinical trial [J]. Lancet Respir Med, 2015, 3(1): 24-32.
[34]	Ahn SY, Chang YS, Kim JH, et al. Two-Year Follow-Up Outcomes of Premature Infants Enrolled in the Phase I Trial of Mesenchymal Stem Cells Transplantation for Bronchopulmonary Dysplasia [J]. J Pediatr, 2017, 185(1):49-54.

相关文章 15

[1]	赵灿斌,邵将,管东辉,秦英,丁强,郭良,王伟伟,陈威,闫小龙,曾平. 木犀草素在炎症微环境下调控Wnt/β-catenin信号通路促进骨髓间充质干细胞成软骨分化的机制[J]. 山东大学学报 (医学版), 2025, 63(7): 11-22.
[2]	刘海霞,皇甫莎莎,桑晓玉,崔东清,毕建忠,王萍. 间充质干细胞对实验性自身免疫性脑脊髓炎小鼠铁死亡的影响[J]. 山东大学学报 (医学版), 2024, 62(6): 1-8.
[3]	沈飞飞,李栋,刘玲红,鞠秀丽. 小肠黏膜下层处理的间充质干细胞片促进伤口愈合[J]. 山东大学学报 (医学版), 2024, 62(4): 68-77.
[4]	王玉淼,崔晓霈,张红雨. 高龄老年新型冠状病毒肺炎患者应用抗凝治疗的短期疗效和安全性[J]. 山东大学学报 (医学版), 2024, 62(12): 21-31.
[5]	闫小龙,秦英,邵将,陈东峰,管东辉,赵灿斌. 姜黄素通过Wnt/β-catenin信号通路调控骨形成的机制[J]. 山东大学学报 (医学版), 2024, 62(10): 76-86.
[6]	赵元元,路军涛,吴小华. 人脐带间充质干细胞外泌体miR-100对多囊卵巢综合征患者颗粒细胞炎症的影响[J]. 山东大学学报 (医学版), 2023, 61(5): 51-58.
[7]	王园园,孙云. 合并新型冠状病毒肺炎的维持性血液透析患者死亡危险因素[J]. 山东大学学报 (医学版), 2023, 61(11): 68-73.
[8]	王成,张淑卉,闫娜,孟林林,陈良志,刘庆华. 脐带间充质干细胞治疗中晚期博来霉素诱导小鼠肺间质纤维化的机制[J]. 山东大学学报 (医学版), 2023, 61(10): 17-22.
[9]	曹义海. 血管生成在疾病治疗中的应用与展望[J]. 山东大学学报 (医学版), 2021, 59(9): 9-14.
[10]	杨璇,李岩志,马伟,贾崇奇. 基于两样本孟德尔随机化的肺功能与新型冠状病毒肺炎病死风险的因果关系[J]. 山东大学学报 (医学版), 2021, 59(7): 104-111.
[11]	周溪,黄霂晗,任玉洁,邱洋. 新型冠状病毒感染与天然免疫及炎症反应[J]. 山东大学学报 (医学版), 2021, 59(5): 15-21.
[12]	于莹,张功,刘晶,颜世童,韩涛,黄海量. 基于网络药理学和分子对接方法探析黄芪预防新型冠状病毒肺炎的潜在作用机制[J]. 山东大学学报 (医学版), 2021, 59(4): 6-16.
[13]	任敏敏,王广梅,张丽,杨瑶瑶,封丹珺. 335名抗疫一线护理人员心理弹性对共情疲劳的影响[J]. 山东大学学报 (医学版), 2021, 59(2): 88-94.
[14]	程召平,段艳华,姚金坤,李岩,顾慧,袁宪顺,刘斌,毕万利,宋照亮,聂佩,陈月芹,孙占国,刘善平,王鲁光,唐忠仁,魏相磊,董亮,王春亭,王锡明. 105例新型冠状病毒肺炎胸部CT影像学特征——山东省多中心回顾性分析[J]. 山东大学学报 (医学版), 2020, 58(5): 38-45.
[15]	袁勇贵,李磊,沈仲夏,陈刚,吴义高,岳莹莹. 新型冠状病毒肺炎疫情下精神障碍诊疗的防控策略[J]. 山东大学学报 (医学版), 2020, 58(4): 1-6.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed